Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 6/20 | 0.50 |
| ▸ | ESR1 | P03372 | 4/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.49 |
| ▸ | PARP1 | P09874 | 2/20 | 0.44 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.44 |
| ▸ | CETP | P11597 | 3/20 | 0.36 |
| ▸ | UTRN | P46939 | 4/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL207162 | 0.90 | ESR2 (0.55) | ESR2ESR1GRM2CETP | |
| SCHEMBL204368 | 0.89 | ESR2 (0.54) | ESR2ESR1GRM2PARP1PARP2 | |
| SCHEMBL205426 | 0.84 | DHODH (0.50) | ESR2ESR1GRM2PARP1PARP2 | |
| SCHEMBL207416 | 0.82 | PARP1 (0.53) | ESR2ESR1PARP1PARP2CETP | |
| SCHEMBL205888 | 0.81 | ESR2 (0.57) | ESR2ESR1PARP1PARP2CETP | |
| SCHEMBL205131 | 0.81 | PARP1 (0.67) | ESR2ESR1PARP1PARP2CETP | |
| SCHEMBL207330 | 0.76 | CETP (0.54) | ESR2ESR1CETPDHODH | |
| SCHEMBL205470 | 0.74 | ESR2 (0.60) | ESR2ESR1CETP | |
| SCHEMBL206041 | 0.74 | ESR2 (0.58) | ESR2ESR1PARP1PARP2CETP | |
| SCHEMBL205527 | 0.73 | ESR2 (0.57) | ESR2ESR1PARP1PARP2CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088760-B2 | Benzoxazole carboxamide inhibitors of poly(ADP-ribose)polymerase (PARP) | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-01-03 | — | — | US | claimed |
| US-20090197863-A1 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-08-06 | — | — | US | claimed |
| US-8088760-B2 | Benzoxazole carboxamide inhibitors of poly(ADP-ribose)polymerase (PARP) | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090197863-A1 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197863-A1 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP2, PARP11 | ESR2 1492/4885ESR1 2161/4885GRM2 3896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.